甲磺酸伊马替尼治疗国人胃肠间质瘤的临床研究

 目的 观察和评价甲磺酸伊马替尼（Imatinib mesylate）治疗国人胃肠间质瘤（GIST）的有效性和安全性。方法 2002年8月至2004年12月，在本院通过病理形态学及免疫组化确诊的GIST共52例，其中36例应用伊马替尼治疗，用法为伊马替尼400mg，口服，1／日。参照WHO实体瘤客观疗效标准观察和判定疗效，NCI-CTC2．0版抗癌药的毒性标准观察和判定毒性。结果 伊马替尼治疗的36例患者中，包括新辅助治疗和姑息治疗在内可以评价疗效的有28例，用药后获得部分缓解为14例（50％），疾病稳定10例（35．7％），疾病进展4例（14．3％）；即有效率（RR）为50％，疾病控制率（DCR）达到85．7％。36例均可进行毒性评价，除了1例因胃部GIST合并脾脏B细胞型非霍奇金淋巴瘤，姑息切除术后口服格列卫同时进行CHOP方案化疗，结果 发生了Ⅲ级骨髓抑制外，其他35例中毒副反应均为Ⅰ～Ⅱ级，而且大多数毒性可以控制或恢复正常。结论 与国外文献报道一致，甲磺酸伊马替尼治疗国人GIST安全高效，耐受性好。

Clinical Study of Chinese Gastrointestinal Stromal Tumors Patients Treated with Imatinib Mesylate

Objective 　To investigate the safety and efficacy of Gastrointestinal St romal Tumors ( GIST) treated with Imatinib mesylate in the Chinise patients. Methods 　52 Chinese GIST patients were diagnosed according to pathology evidence as well as IHC positive CD117 st rain and t reated in Bayi hospital from Aug. 2002 to Dec. 2004. The GIST pts treated with Imatinib mesylate (usage : 400 mg , PO , qd) were carefully observed for efficacy and safety according to WHO and NCI-CTC V2. 0 standards , respectively. Results 　Totally , there are 36 GIST pts treated with Imatinib , 28 pts might be evaluated for the efficacy. There were 14 patient s (50 % ) got PR , 10 pts (35. 7 %) SD over 6 months , only 4 pts (14. 3 %) got PD. That was RR 50 % or DCR 85. 7 %. 36 pts might be evaluated for the toxicity. Except one GIST patient complicated with Non-Hodgkin’s lymphoma treated with Imatinib and CHOP regimenchemotherapy showed III grade hypohematocyte , only I～II grade adverse reactions occurred in other 35 pts. Conclusion 　Those result s are consistent with foreigner’ s reports. Imatinib is a safe and efficacious molecular target drug used for Chinese GIST. Only mild adverse reactions occur in t reated patient s. It is worth to use Imatinib widely and clinically.